Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • RESEARCH HIGHLIGHT

A vaccine against the cervical-cancer virus shows its prowess

In a large trial, not a single participant developed a serious precancerous lesion caused by a vaccine-targeted viral type.
Cervical cancer cells, coloured scanning electron micrograph (SEM).

Cervical cancer cells (artificially coloured). Some 90% of cervical cancers are caused by infection with human papillomavirus. Credit: Anne E. Weston/SPL

A decade-long clinical trial in 13 countries across 5 continents reaffirms that a vaccine targeting 9 strains of human papillomavirus (HPV) provides long-lasting protection1.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 621, 447 (2023)

doi: https://doi.org/10.1038/d41586-023-02830-z

References

  1. Restrepo, J. et al. Pediatrics 152, e2022060993 (2023).

    Article  Google Scholar 

Download references

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links